Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00028145 |
|
Recruitment Status :
Completed
First Posted : December 14, 2001
Last Update Posted : October 10, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to collect and study clinical and laboratory information about a pregnant or new mother and her medical care that will increase our knowledge of the best care for HIV-infected pregnant women and their children.
The rate of transmission of HIV from mothers to their infants has gone down. Specific U.S. Public Health Service guidelines recommend that HIV-infected pregnant women be treated with anti-HIV therapies; but the effectiveness of treatment and safety for the mother and her infant have not been fully examined. This study will monitor the health of women and their infants while they receive anti-HIV therapy. Also, this study will provide information that may be used for future studies.
| Condition or disease | Intervention/treatment |
|---|---|
| HIV Infections Pregnancy Complications, Infectious | Behavioral: Adherence assessment |
The current low rate of vertical transmission of HIV in the U.S. limits the number and types of questions concerning transmission risk and pathogenesis that can be addressed by a single clinical trial. Specific U.S. Public Health Service guidelines recommend antiretroviral therapy (ART) during pregnancy to maximize health of women. However, data regarding the effectiveness and safety of and adherence to ART during pregnancy are limited. It is both appropriate and necessary for theInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) to recruit pregnant women into a non-interventional, analytic, epidemiologic study to methodically collect clinical and laboratory data from them and their infants. This way, the IMPAACT can achieve the aims of evaluating management of HIV-infected women during pregnancy and determining the safety and effectiveness of ART and other interventions intended to prevent vertical transmission and/or improve maternal health. In addition, longitudinally collected core protocol data and repository specimens will enable future substudies.
Participants receive no protocol specific treatment or other intervention as part of this study. The study involves the follow-up of HIV-infected women enrolled during pregnancy or at the time of delivery for 6 months postpartum and their infants for the first 6 months of life. There will be 8 study visits for enrolled participants and 6 study visits for infants. Data concerning ART use, adherence to medications, and review of symptoms relevant to side effects and toxicities are collected through administration of questionnaires at all maternal visits. Phlebotomy is conducted to obtain specimens for a repository and for required laboratory tests. During labor and delivery, maternal blood is obtained for lymphocyte subset and viral load assays and for repository storage. Collection of amniotic fluid at the time of cesarean section is encouraged. These collections are submitted to a central repository. Data for the core protocol are abstracted from the infant's medical record at the time of birth and at each postnatal visit.
| Study Type : | Observational |
| Actual Enrollment : | 3090 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Perinatal Core Protocol |
| Study Start Date : | October 2002 |
| Actual Primary Completion Date : | June 2013 |
| Actual Study Completion Date : | June 2013 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
1
Pregnant, HIV-infected women
|
Behavioral: Adherence assessment
Adherence will be assessed using questionnaires at all study visits. |
- Maternal and infant response to prescribed interventions [ Time Frame: Throughout study ]
- Immune and viral parameters of participants taking prescribed interventions [ Time Frame: Throughout study ]
- Occurrences of genotypic and phenotypic resistance in HIV-infected mothers [ Time Frame: Throughout study ]
- Clinical, immunological, and virological responses in HIV-infected women [ Time Frame: Throughout study ]
- Mother-to-child transmission rates of resistance mutations [ Time Frame: Throughout study ]
- Adherence to ART among HIV-infected pregnant women during pregnancy and postpartum [ Time Frame: Throughout study ]
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 14 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- HIV infected
- At least 14 weeks pregnant OR have delivered a liveborn or stillborn infant and are within 14 days of the delivery
- Currently receiving care at an IMPAACT or other participating site
- Have a parent or guardian willing to provide signed informed consent, if applicable
- Mentally capable of giving informed consent to have the infant and self followed at an IMPAACT site
Exclusion Criteria:
- Intend to end the pregnancy
- Unable to come for a study visit within 14 days after delivery (if known to be HIV infected prior to delivery) OR within 28 days after delivery (if found to be HIV infected at the time of labor and delivery or within 14 days after delivery)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00028145
Show 77 Study Locations
| Study Chair: | Ruth Tuomala, MD | Director of Obstetrics and Gynecology, Brigham and Women's Hospital | |
| Study Chair: | Gwen Scott, MD | Pediatric Infectious Diseases, University of Miami School of Medicine |
Additional Information:
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
| ClinicalTrials.gov Identifier: | NCT00028145 History of Changes |
| Other Study ID Numbers: |
PACTG P1025 U01AI068632 ( U.S. NIH Grant/Contract ) |
| First Posted: | December 14, 2001 Key Record Dates |
| Last Update Posted: | October 10, 2014 |
| Last Verified: | October 2014 |
|
Women's Health Disease Transmission, Vertical Preventive Medicine Treatment Experienced |
|
Pregnancy Complications, Infectious Pregnancy Complications Infection |